The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study M.A.

Slides:

Advertisements

Similar presentations

Efficacy of ultrasound therapy for the management of knee osteoarthritis: a systematic review with meta-analysis A. Loyola-Sánchez, J. Richardson, N.J.

Advertisements

IκB kinase inhibition as a potential treatment of osteoarthritis – results of a clinical proof- of-concept study K. Grothe, K. Flechsenhar, T. Paehler,

Type II collagen C2C epitope in human synovial fluid and serum after knee injury – associations with molecular and structural markers of injury N. Kumahashi,

Knee osteoarthritis radiographic progression and associations with pain and function prior to knee arthroplasty: a multicenter comparative cohort study

Exercise, education, manual-therapy and taping compared to education for patellofemoral osteoarthritis: a blinded, randomised clinical trial K.M. Crossley,

Short-term placebo response in trials of patients with symptomatic osteoarthritis: differences between hip and knee S. Reiter-Niesert, M. Boers, J. Detert

Efficacy of patient education and supervised exercise vs patient education alone in patients with hip osteoarthritis: a single blind randomized clinical.

Effects of dietary weight loss with and without exercise on interstitial matrix turnover and tissue inflammation biomarkers in adults with knee osteoarthritis:

Inflammation and post-operative recovery in patients undergoing total knee arthroplasty- secondary analysis of a randomized controlled trial A. Langkilde,

Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation B.C. Sondergaard,

Glucosamine but not ibuprofen alters cartilage turnover in osteoarthritis patients in response to physical training S.G. Petersen, T. Saxne, D. Heinegard,

P.-S. Hsu, H.-H. Lin, C.-R. Li, W.-S. Chung

B.J. Ahern, J. Parvizi, R. Boston, T.P. Schaer

Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double-blind, placebo-controlled study

B.J. Ahern, J. Parvizi, R. Boston, T.P. Schaer

Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized,

A prospective randomized comparison of neoprene vs thermoplast hand-based thumb spica splinting for trapeziometacarpal arthrosis S.J.E. Becker, A.G.J.

Sustained efficacy of a single intra-articular dose of FX006 in a rat model of repeated localized knee arthritis A. Kumar, A.M. Bendele, R.C. Blanks,

Osteoarthritis year 2011 in review: biochemical markers of osteoarthritis: an overview of research and initiatives Y. Henrotin Osteoarthritis and Cartilage

Cross-cultural adaptation and implementation of Good Life with osteoarthritis in Denmark (GLA:D™): group education and exercise for hip and knee osteoarthritis.

K. Zou, M.D., G. Liu, M.D., T. Wu, M.D., L. Du, M.D.

Oral salmon calcitonin reduces cartilage and bone pathology in an osteoarthritis rat model with increased subchondral bone turnover R.H. Nielsen, A.-C.

Dose-response relationship between ambulatory load magnitude and load-induced changes in COMP in young healthy adults S. Herger, W. Vach, A.-M. Liphardt,

Transdermal buprenorphine plus oral paracetamol vs an oral codeine-paracetamol combination for osteoarthritis of hip and/or knee: a randomised trial

Efficacy and safety of intraarticular hyaluronic acid in the treatment of hip osteoarthritis: a systematic review J.C. Fernández López, M.D., Ph.D.,

Anabolic and catabolic function of chondrocyte ex vivo is reflected by the metabolic processing of type II collagen A.K. Olsen, M.Sc., B.C. Sondergaard,

The relative efficacy of topical non-steroidal anti-inflammatory drugs and capsaicin in osteoarthritis: a network meta-analysis of randomised controlled.

Calcitonin directly attenuates collagen type II degradation by inhibition of matrix metalloproteinase expression and activity in articular chondrocytes

Time to be positive about negative data?

Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results.

Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized,

Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta- analysis of randomized placebo-controlled trials E.M. Bartels,

Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain R.J. Benschop, E.C. Collins, R.J.

J. Avouac, M.D., L. Gossec, M.D., M. Dougados, M.D.

The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination C.G. Jackson, A.H. Plaas, J.D.

OA phenotypes, rather than disease stage, drive structural progression – identification of structural progressors from 2 phase III randomized clinical.

Mice over-expressing salmon calcitonin have strongly attenuated osteoarthritic histopathological changes after destabilization of the medial meniscus

Stem cell therapy for human cartilage defects: a systematic review

Evaluations of radiographic joint space – do they adequately predict cartilage conditions in the patellofemoral joint of the patients undergoing total.

A relationship between mechanically-induced changes in serum cartilage oligomeric matrix protein (COMP) and changes in cartilage thickness after 5 years

Baseline and longitudinal change in isometric muscle strength prior to radiographic progression in osteoarthritic and pre-osteoarthritic knees – data.

A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee

Efficacy of low frequency pulsed subsensory threshold electrical stimulation vs placebo on pain and physical function in people with knee osteoarthritis:

A new lipid formulation of low dose (1200mg) ibuprofen is non-inferior to high dose (2400mg) standard ibuprofen capsules in managing episodic knee pain.

M. A. Karsdal, M. Sc. , Ph. D. , D. J. Leeming, M. Sc. , E. B. Dam, M

Scientific production and impact of national registers: the example of orthopaedic national registers P. Boyer, I. Boutron, P. Ravaud Osteoarthritis.

Efficacy and safety of ginger in osteoarthritis patients: a meta-analysis of randomized placebo-controlled trials E.M. Bartels, V.N. Folmer, H. Bliddal,

Who should have a joint replacement? A plea for more ‘phronesis’

Knee Injury and Osteoarthritis Outcome Score (KOOS): systematic review and meta- analysis of measurement properties N.J. Collins, C.A.C. Prinsen, R. Christensen,

Volumetric bone mineral density of the tibia is not increased in subjects with radiographic knee osteoarthritis M. Abdin-Mohamed, M.B.B.S., M.R.C.P.,

Identification of serological biomarker profiles associated with total joint replacement in osteoarthritis patients R.H.G.P. Arends, M.A. Karsdal, K.M.

IκB kinase inhibition as a potential treatment of osteoarthritis – results of a clinical proof- of-concept study K. Grothe, K. Flechsenhar, T. Paehler,

Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials M.A. Karsdal, I. Byrjalsen, P. Alexandersen,

Erratum to “MMP and non-MMP-mediated release of aggrecan and its fragments from articular cartilage: a comparative study of three different aggrecan and.

Does pre-surgical central modulation of pain influence outcome after total knee replacement? A systematic review I.A.C. Baert, E. Lluch, T. Mulder, J.

D.J. Hunter Osteoarthritis and Cartilage

The association between hip bone marrow lesions and bone mineral density: a cross- sectional and longitudinal population-based study H. Ahedi, D. Aitken,

A Double-Blind, Randomized, Crossover Comparison Between Single-Dose and Double-Dose Immediate-Release Oral Morphine at Bedtime in Cancer Patients Ola.

Limited effects of exercises in people with hand osteoarthritis: results from a randomized controlled trial N. Østerås, K.B. Hagen, M. Grotle, A.-L.

C. Ratzlaff, M. Koehoorn, J. Cibere, J. Kopec

Osteoarthritis year 2012 in review: biology

L.A. Deveza, L. Melo, T.P. Yamato, K. Mills, V. Ravi, D.J. Hunter

Systematic review of the impact of osteoarthritis on health outcomes for comorbid disease in older people L. Parkinson, D.L. Waters, L. Franck Osteoarthritis.

Effect of glucosamine supplementation on fasting and non-fasting plasma glucose and serum insulin concentrations in healthy individuals Allison J. Tannis,

Osteoarthritis year in review 2016: mechanics

Symptomatic efficacy of avocado–soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials R. Christensen,

M. Doherty, P. Dieppe Osteoarthritis and Cartilage

Measurement of synovial fluid volume using urea

Effect of a 16 weeks weight loss program on osteoarthritis biomarkers in obese patients with knee osteoarthritis: a prospective cohort study E.M. Bartels,

General Information Osteoarthritis and Cartilage

Presentation transcript:

The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study M.A. Karsdal, I. Byrjalsen, K. Henriksen, B.J. Riis, E.M. Lau, M. Arnold, C. Christiansen Osteoarthritis and Cartilage Volume 18, Issue 2, Pages 150-159 (February 2010) DOI: 10.1016/j.joca.2009.08.004 Copyright © 2009 Osteoarthritis Research Society International Terms and Conditions

Fig. 1 Flow diagram giving the number of subjects screened, number of subjects allocated, number of subjects at follow-up, and number of subjects analyzed. Osteoarthritis and Cartilage 2010 18, 150-159DOI: (10.1016/j.joca.2009.08.004) Copyright © 2009 Osteoarthritis Research Society International Terms and Conditions

Fig. 2 Time course of plasma sCT concentrations in the 4h following dosing with 0.6mg sCT (open circles), 0.8mg sCT (closed circles), and placebo (dotted line). Upper panel is dosing at treatment day 1 with doses given at 08:00 and 17:00. Lower panel is dosing at treatment day 14 with doses given at 08:00 and 17:00. Values shown are geometric mean ±1 s.e.m. Osteoarthritis and Cartilage 2010 18, 150-159DOI: (10.1016/j.joca.2009.08.004) Copyright © 2009 Osteoarthritis Research Society International Terms and Conditions

Fig. 3 AUC of plasma sCT concentrations in the 4h following dosing at 08:00 (upper panel) and 17:00. (lower panel). Values shown are geometric mean ±1 s.e.m. Osteoarthritis and Cartilage 2010 18, 150-159DOI: (10.1016/j.joca.2009.08.004) Copyright © 2009 Osteoarthritis Research Society International Terms and Conditions

Fig. 4 Time course and AUC of serum CTX-I following dosing with 0.6mg sCT (open circles), 0.8mg sCT (closed circles), and placebo (dotted line). Upper panel is dosing at treatment day 1 with doses given at 08:00 and 17:00. Middle panel is dosing at treatment day 14 with doses given at 08:00 and 17:00. Values shown are levels relative to the pre-dose concentration measured in blood samples taken immediately prior to dosing at 08:00. Lower panel gives the AUC of the change in relative levels from 08:00 to 21:00 Values given are mean ±1 s.e.m. Tukey–Kramer adjusted significance levels of treatment effect against placebo: ***P<0.001. Osteoarthritis and Cartilage 2010 18, 150-159DOI: (10.1016/j.joca.2009.08.004) Copyright © 2009 Osteoarthritis Research Society International Terms and Conditions

Fig. 5 Time course and AUC of urine CTXII following dosing with 0.6mg sCT (open circles), 0.8mg sCT (closed circles), and placebo (dotted line). Upper panel is dosing at treatment day 1 with doses given at 08:00 and 17:00. Middle panel is dosing at treatment day 14 with doses given at 08:00 and 17:00. Values shown are levels relative to the pre-dose concentration measured in blood samples taken immediately prior to dosing at 08:00. Lower panel gives the AUC of the change in relative levels from 08:00 to 21:00 Values given are mean ±1 s.e.m. Tukey–Kramer adjusted significance levels of treatment effect against placebo: **P<0.01; ***P<0.001. Osteoarthritis and Cartilage 2010 18, 150-159DOI: (10.1016/j.joca.2009.08.004) Copyright © 2009 Osteoarthritis Research Society International Terms and Conditions

Fig. 6 Time course and AUC of serum OC following dosing with 0.6mg sCT (open circles), 0.8mg sCT (closed circles), and placebo (dotted line). Upper panel is dosing at treatment day 1 with doses given at 08:00 and 17:00. Middle panel is dosing at treatment day 14 with doses given at 08:00 and 17:00. Values shown are levels relative to the pre-dose concentration measured in blood samples taken immediately prior to dosing at 08:00. Lower panel gives the AUC of the change in relative levels from 08:00 to 21:00 Values given are mean ±1 s.e.m. Tukey–Kramer adjusted significance levels of treatment effect against placebo: ***P<0.001. Osteoarthritis and Cartilage 2010 18, 150-159DOI: (10.1016/j.joca.2009.08.004) Copyright © 2009 Osteoarthritis Research Society International Terms and Conditions